Clinical Trials Logo

Refractory Renal Cell Carcinoma clinical trials

View clinical trials related to Refractory Renal Cell Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05935748 Recruiting - Neoplasms Clinical Trials

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Start date: July 28, 2023
Phase: Phase 2
Study type: Interventional

The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.

NCT ID: NCT05119335 Recruiting - Clinical trials for Renal Cell Carcinoma

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Start date: October 26, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.